Click here to learn more

Scroll over the words in bold for brief definitions.

ILARIS®—Safety Profile Over 48 Weeks*

Important Safety Information

  • A total of 9 serious adverse reactions were reported with ILARIS® in clinical trials, including infections and vertigo
    • 1 patient discontinued treatment with ILARIS® due to potential infection
  • 9% of patients experienced injection-site reactions overall
    • No severe injection-site reactions were reported with treatment with ILARIS®
Images of urticaria, conjunctivitis & arthralgia
None of these AEs led to discontinuation of ILARIS®
  • Infections, predominantly of the upper respiratory tract, in some instances serious, have been reported with ILARIS®†
    • Generally, the observed infections responded to standard therapy
    • Isolated cases of unusual or opportunistic infections were reported during ILARIS® treatment
  • None of the patients receiving ILARIS® developed antibodies to treatment†
    • 31 of 60 patients received ILARIS® for more than 48 weeks
    • Data obtained in an assay are highly dependent on several factors. Comparison of the incidence of antibodies between ILARIS® and other products may be misleading

    *Study design: The pivotal study consisted of a 48-week, 3-part, multicenter study, ie, an 8-week, open-label period (Part 1); a 24-week, randomized, double-blind, placebo-controlled withdrawal period (Part 2); followed by a 16-week, open-label period (Part 3) in 35 patients.
    †These data reflect exposure to ILARIS® in 104 adult and pediatric CAPS patients in placebo-controlled (35 patients) and uncontrolled trials.

    Important Safety Information

    ILARIS® is contraindicated in patients with confirmed hypersensitivity to the active substance or to any of the excipients.

    ILARIS® may be associated with an increased risk of serious infections. Physicians should exercise caution when administering ILARIS® to patients with infections, a history of recurring infections or underlying conditions which may predispose them to infections.

    ILARIS should not be administered to patients during an active infection requiring medical intervention. Administration of ILARIS® should be discontinued if a patient develops a serious infection.

    In clinical trials, ILARIS has not been administered concomitantly with tumor necrosis factor (TNF) inhibitors. An increased incidence of serious infections has been associated with administration of another IL-1 blocker in combination with TNF inhibitors. Co-administration of ILARIS with TNF inhibitors is not recommended because this may increase the risk of serious infections.

    Drugs that affect the immune system by blocking TNF have been associated with an increased risk of new tuberculosis and reactivation of latent tuberculosis (TB). It is possible that use of IL-1 inhibitors such as ILARIS increases the risk of reactivation of TB or of opportunistic infections.

    Prior to initiating immunomodulatory therapies, including ILARIS, patients should be evaluated for active and latent tuberculosis infection. Appropriate screening tests should be performed on all patients. ILARIS has not been studied in patients with a positive tuberculosis screen, and the safety of ILARIS in individuals with latent tuberculosis infection is unknown. Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with ILARIS. All patients should be instructed to seek medical advice if signs, symptoms, or high risk exposure suggestive of tuberculosis (e.g. persistent cough, weight loss, subfebrile temperature) appear during or after ILARIS therapy.

    The impact of treatment with anti-interleukin-1 (IL-1) therapy on the development of malignancies is not known. However, treatment with immunosuppressants, including ILARIS, may result in an increase in the risk of malignancies.

    Hypersensitivity reactions have been reported with ILARIS therapy. No anaphylactic reactions have been reported. It should be recognized that symptoms of the underlying disease being treated may be similar to symptoms of hypersensitivity.

    Live vaccines should not be given concurrently with ILARIS. Prior to initiation of therapy with ILARIS, patients should receive all recommended vaccinations. In addition, because ILARIS may interfere with normal immune response to new antigens, vaccinations may not be effective in patients receiving ILARIS.

    Serious adverse reactions reported with ILARIS in the CAPS clinical trials included infections and vertigo. The most commonly reported adverse reactions associated with ILARIS treatment in CAPS patients were nasopharyngitis, diarrhea, influenza, headache, and nausea.